1,721,046 research outputs found
BIOLOGIC THERAPY IN INFLAMMATORY AND IMMUNOMEDIATED ARTHRITIS: SAFETY PROFILE
No full textThe increasing insights into the pathogenetic mechanisms of inflammatory autoimmune arthritis and the development of innovative systems of industrial production have led to discover molecules which are targeted at molecules involved in the mechanisms of the immune system and that have been introduced in clinical practice to provide an alternative to the existing treatment methods of disease-modifying anti-rheumatic drugs and other immunosuppressive medications. For this reason, such drugs are currently known as "biological drugs" and include molecules that induce the immunosuppression acting on several immune pathways. However, though the biological drugs have been employed from more than a decade, there still exist some drawbacks of their use, including the inconvenience of intravenous administration, the high costs, and adverse events associated with them. This review provides an update on the correct use and current therapeutic indications of such drugs, including some of the new biologic therapies that will be soon available for the clinical use, focusing on these biological drugs: tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab-pegol, etanercept, golimumab and infliximab); the T cell co-stimulation inhibitor, abatacept; the anti-CD20 receptor monoclonal B cell agent, rituximab; the IL-6 receptor-blocking monoclonal antibody, tocilizumab; the IL-1-inhibitor, anakinra; the IL-17-pathway inhibitors (ustekinumab, secukinumab, brodalumab)
5-methylcytosine content of DNA in blood and synovial mononuclear cells and in synovial tissue from patients affected by rheumatic autoimmune disease.
No full text
Biologics in inflammatory and immunomediated arthritis
No full textBiologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis
Biomarkers in Inflammatory Bowel Disease-Associated Spondyloarthritis: State of the Art and Unmet Needs
Get PDFInflammatory bowel disease-associated spondyloarthritis is a systemic disease characterized by the chronic inflammation of both the gastrointestinal tract and the musculoskeletal system. Since inflammatory bowel disease-associated spondyloarthritis has been associated with a significant diagnostic delay, which may lead to poor quality of life and progression of joint damage, efforts to discover new reliable and noninvasive diagnostic biomarkers have been made. We reviewed the state of the art of biomarker research in inflammatory bowel disease-associated spondyloarthritis, showing that to date it has been largely unsatisfactory. Only a few of the biomarkers that have been investigated are likely to enter the clinical practice upon further validation in independent cohorts. The research of new and innovative biomarkers for inflammatory bowel disease-associated spondyloarthritis is warranted
Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: A review of the literature
No full textNew Insights in Physical Therapy and Rehabilitation in Psoriatic Arthritis: A Review
No full textPsoriatic arthritis (PsA) is a complex, multiform and chronic inflammatory disease characterized by the association of psoriasis and arthritis with other musculoskeletal and extra-articular manifestations. The treatment of PsA is rapidly evolving due to the introduction of new biologic and small-molecule drugs, and the aim of treatment is to induce a condition of remission or low disease activity in all disease domains. However, unmet treatment needs still persist for those patients with impaired function, reduced quality of life or comorbidities. In this context, physical therapy and rehabilitation could provide additional benefits by reducing disease activity and improving function. Although a large number of studies have assessed the role of physical therapy and exercise in other forms of chronic inflammatory arthritis, such as axial spondyloarthritis and rheumatoid arthritis, evidence on their effect on persons with PsA is still lacking. However, some studies have reported the potential positive role of physical therapy on the different disease domains of PsA, in helping to improve disease activity, prevent or improve articular impairment, improve pain management and improve quality of life. Here, we review current evidence on physical therapy, exercise and rehabilitation in patients with PsA. In particular, we review the literature focusing on each domain, to provide evidence of efficacy and effectiveness of exercise and rehabilitation on skin, peripheral arthritis, axial involvement, dactylitis, enthesitis and comorbidities
- …
